Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysisAlessandro Rizzo, Mario Giuliano, Grazia Arpino et al.|ESMO Open|2023Cited by 31
266P Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysisFrancesca Matilde Schipilliti, Mario Giuliano, Alessandro Rizzo et al.|Annals of Oncology|2023Cited by 0